Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.

International journal of geriatric psychiatry - 1 Apr 2012

Kennelly Sean, Abdullah Laila, Kenny Rose Anne, Mathura Venkat, Luis Cheryl A, Mouzon Benoit, Crawford Fiona, Mullan Michael, Lawlor Brian

Abstract excerpt

BACKGROUND: Evidence suggests that dihydropyridine calcium channel blockers may be useful in preventing and treating Alzheimer's disease (AD). OBJECTIVE: In an open-label trial of safety and tolerability of nilvadipine in patients with AD, we examined cognition and executive function over a short time period to determine an influence of nilvadipine on these outcomes. METHOD: We investigated change in cognition...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antihypertensive Agents

Share to Apolipoprotein E4

Share to Cognition

Share to Cohort Studies

Share to Executive Function

Share to Nifedipine

Source

Identifiers

PMID: 21560164
DOI: 10.1002/gps.2735

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.PMID 21560164Read ↗

Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Delayed Decline of Cognitive Function by Antihypertensive Agents: A Cohort Study Linked with Genotype Data.Semantic proximity Read ↗

Safety, tolerability and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD) trialSemantic proximity Read ↗

Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone.Semantic proximity Read ↗

Effect of initiating an ARB- versus ACEI-based regimen on dementia risk, a target trial emulation of 2.5 million US VeteransSemantic proximity Read ↗

Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's diseaseSemantic proximity Read ↗

Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program.Semantic proximity Read ↗

Detailed cognitive function and use of drugs with anticholinergic properties in older people: a community-based cross-sectional study.Semantic proximity Read ↗

Apolipoprotein E genotypes and the incidence of Alzheimer's disease among persons aged 75 years and older: variation by use of antihypertensive medication?Semantic proximity Read ↗

Safety and Efficacy of Donepezil 10 mg/day in Patients with Mild to Moderate Alzheimer's Disease.Semantic proximity Read ↗

Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele.Semantic proximity Read ↗

Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.